tariquidar has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Béni, Z; Dékány, M; Hohmann, J; Spengler, G; Szemerédi, N; Ványolós, A; Yazdani, M | 1 |
| Ma, L; Panyam, J; Patil, Y; Sadhukha, T | 1 |
1 review(s) available for tariquidar and Adenocarcinoma
| Article | Year |
|---|---|
Triterpenes from
Topics: Adenocarcinoma; Agaricales; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Cytotoxins; Drug Resistance, Multiple; Ergosterol; Humans; Molecular Structure; Triterpenes | 2022 |
1 other study(ies) available for tariquidar and Adenocarcinoma
| Article | Year |
|---|---|
Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Lactic Acid; Leukemia, T-Cell; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinolines | 2009 |